Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

Type of Cancer
Lung

Phase

Division (Location)

Study ID

NCT#

Brief Description
Phase I/II study of Dasatinib and Osimertinib (AZD9291) in patients with advanced non-small cell lung cancer with EGFR mutations

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.